Myriad Geneticsの空売り状況は、投資家がMyriad Geneticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Myriad Genetics (NASDAQ:MYGN) 株価情報, 空売り情報

Myriad Genetics

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics Inc

News

ILMN

MYGN

Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay

Across the recent three months, 4 analysts have shared their insights on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.0, a high estimate of $35.00, and a low estimate of $21.00. This current average has decreased by 9.68% from the previous average price target of $31.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731938459_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Myriad Genetics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Myriad Genetics</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Myriad Genetics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 11.15%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's net margin excels beyond industry benchmarks, reaching -10.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Myriad Genetics's ROE excels beyond industry benchmarks, reaching -3.0%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Myriad Genetics's ROA excels beyond industry benchmarks, reaching -2.04%. This signifies efficient management of assets and strong financial health.
Debt Management: Myriad Genetics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.2. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where Myriad Genetics Stands With Analysts

Morgan Stanley analyst Tejas Savant maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Equal-Weight and lowers the price target from $32 to $21.

Price Target

Morgan Stanley Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $21

Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral and lowers the price target from $30 to $24.

Piper Sandler Maintains Neutral on Myriad Genetics, Lowers Price Target to $24

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. The company reported quarterly sales of $213.300 million which beat the analyst consensus estimate of $210.729 million by 1.22 percent. This is a 11.15 percent increase over sales of $191.900 million the same period last year.

Earnings

Earnings Beats

Myriad Genetics Q3 2024 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $213.300M Beat $210.729M Estimate

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) raises FY2024 Adj EPS guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 analyst estimate. Narrows FY2024 sales outlook from $835.00 million-845.00 million to $837.00 million-843.00 million vs $841.44 million estimate.

Guidance

Myriad Genetics Raises FY2024 Adj EPS Guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 Est; Narrows FY2024 Sales Guidance from $835.00M-845.00M to $837.00M-843.00M vs $841.44M Est

<a href="https://www.globenewswire.com/Tracker?data=7IgUCHg5VDTZmZv9O5dmpuSulHxlAJX4J-7gHq9u70JsTOLd46YDQ3PHfeC3CPV33eEopeKpgDqehovhXYmsMg==">Myriad Genetics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025.
After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverage of GeneSight. Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test, GeneSight, and is seeking to ensure that enrollees continue to have access to the test.

Biotech

General

Myriad Genetics Was Informed On Friday, November 1, 2024, Of An Updated Medical Policy From UnitedHealthCare Restricting Access To Multi-Gene Panel Pharmacogenetic Tests, Including Myriad's Genesight Test, Under Its Commercial And Individual Exchange Benefit Plans, Effective January 1st, 2025

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Friday.
The Dow traded up 0.67% to 42,043.38 while the NASDAQ surged 0.75% to 18,230.53. The S&amp;P 500 also rose, gaining, 0.47% to 5,732.21.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.3% on Friday.
In trading on Friday, utilities shares fell by 2.1%.
Top Headline
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell around 2% on Friday after the company reported results for the fourth quarter.
The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share.
<h3 class="wp-block-heading">Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 53% to $5.34 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 33% to $36.42 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.23 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 71% to $1.51 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.30. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 37% to $1.2250. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $69.79 while gold traded down 0.1% at $2,745.60.
Silver traded down 0.7% to $32.555 on Friday, while copper rose 0.3% to $4.3520.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.09%, Germany's DAX gained 0.93% and France's CAC 40 gained 0.80%. Spain's IBEX 35 Index surged 1.46%, while London's FTSE 100 rose 0.83%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
<li>The total number of active U.S. oil rigs fell by one to 479 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

Equities

Eurozone

Commodities

Markets

Trading Ideas

AAPL

CDXC

EPIX

LXRX

PRLB

TILE

Crude Oil Moves Higher; Apple Shares Slide After Q4 Results

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 50.3% to $0.64 during Friday's regular session. The market value of their outstanding shares is at $24.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 45.55% to $5.08. The market value of their outstanding shares is at $385.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares rose 27.44% to $1.86. The company's market cap stands at $2.5 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares rose 26.41% to $1.11. The company's market cap stands at $4.0 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 25.53% to $38.94. The market value of their outstanding shares is at $130.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) stock increased by 20.73% to $14.88. The market value of their outstanding shares is at $1.2 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 35.1% to $1.26 during Friday's regular session. The market value of their outstanding shares is at $457.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 22.44% to $11.1. The market value of their outstanding shares is at $12.7 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 21.57% to $17.23. The company's market cap stands at $1.5 billion. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock fell 14.0% to $14.99. The market value of their outstanding shares is at $918.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 13.42% to $1.06. The company's market cap stands at $5.9 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 12.38% to $0.5. The market value of their outstanding shares is at $36.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

ATHA

BFRI

ALPS ETF Trusthen & Steers Global Realty Majors ETF

PDEX

PLSE

TOVX

XAIR

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday.
The Dow traded up 1.18% to 42,254.81 while the NASDAQ surged 1.31% to 18,332.35. The S&amp;P 500 also rose, gaining, 0.95% to 5,759.63.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.9% on Friday.
In trading on Friday, utilities shares fell by 1.1%.
Top Headline
Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares surged 7% on Friday after the copany posted stronger-than-expected results for the third quarter.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 55% to $5.41 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 31% to $36.54 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.15 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 70% to $1.58 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.24. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 36% to $1.2550. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $70.04 while gold traded up 0.2% at $2,753.70.
Silver traded down 0.1% to $32.755 on Friday, while copper rose 0.5% to $4.3635.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.25%, Germany's DAX gained 1.10% and France's CAC 40 gained 1.05%. Spain's IBEX 35 Index surged 1.42%, while London's FTSE 100 rose 1.06%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

AMZN

Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results

Myriad Genetics Reaffirms Previously Issued FY24 Revenue And Adj. Guidance Previously Provided On August 6 During Its Q2 Earnings Call

In addition, based partially on the Company&#39;s preliminary results for the third quarter of 2024, the Company is reaffirming its previously issued revenue and non-GAAP financial guidance for the full-year 2024 previously provided on August 6, 2024 during its second quarter 2024 earnings call. This guidance included full year 2024 revenue expectations of between $835 million and $845 million.

Myriad Genetics Discloses Certain Preliminary Financial Data For Q3, Expects Revenue Of $210M - $212M (Est $209.397M), Despite Divestiture Of EndoPredict Business In Europe - Filing

Myriad Genetics Reveals Series Of Ongoing Research Collaborations To Study Use Of Molecular Residual Disease Testing In Breast Cancer Using Precise MRD Test

<a href="https://www.globenewswire.com/Tracker?data=FaeImwHFSrdIr3Whx5NVoW1Uj1rIQl4XG_FGofXhlX3u3Hg9zWoRBS2wyn2_cPl9zqQKwcmHujJ1-24smichVLBsgCbeDbvSbf3jhCAsrf4nCgsEQb-2zL4hbX1eOBuCM4tBmkCozNBxfp5RNdWvdXy2-oKG0q2mSG-Nn8TbMK-bF_Z_rriuwZe7iU9aGiPd8WhyZLAhjSx7GWYbp5qmcbVbLe6xxWy8VMFfi7CY1Ls=">Myriad Genetics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima's UG 100&#x2122;&nbsp;sequencing platform and its ppmSeq&#x2122;&nbsp;technology to advance Myriad's ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco. &nbsp;
The low-cost and low-error sequencing achievable on the UG 100 may benefit several of Myriad's emerging products that require large amounts of high-fidelity sequencing data. The Myriad Precise Molecular Residual Disease (MRD) test performs whole-genome sequencing on two samples from cancer patients—one from a tumor and one from normal tissue—to comprehensively identify tumor-specific variants for subsequent tracking in a personalized panel. With Ultima's support, Myriad will explore the potential for the Precise MRD test to improve in both performance and cost with ppmSeq on the UG 100. In the reproductive-health space, Myriad is expected to launch its FirstGene Multiple Prenatal Screen, which will run the content of multiple prenatal screens via a single sequencing workflow. FirstGene also requires deep and accurate sequencing that the UG 100 platform may be well suited to affordably provide.

Myriad Genetics And Ultima Genomics To Explore The UG 100 Sequencing Platform To Advance Clinical Test Offerings In Oncology And Reproductive Genomics

Myriad Genetics Says USPTO Issued Third Patent For Molecular Residual Disease With Early Priority Date

7 analysts have shared their evaluations of Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $30.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 17.65% increase, the current average has risen from the previous average price target of $25.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1726747212_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Myriad Genetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$34.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Myriad Genetics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Myriad Genetics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
<h2>Get to Know Myriad Genetics Better</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Financial Insights: Myriad Genetics</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 15.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Myriad Genetics's net margin is impressive, surpassing industry averages. With a net margin of -17.35%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.89%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.34%, the company showcases effective utilization of assets.
Debt Management: Myriad Genetics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.19, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Myriad Genetics's Future

Morgan Stanley analyst Tejas Savant initiates coverage on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Equal-Weight rating and announces Price Target of $32.

Initiation

Morgan Stanley Initiates Coverage On Myriad Genetics with Equal-Weight Rating, Announces Price Target of $32

U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.
Shares of G-III Apparel Group, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) rose sharply during Thursday's session after the company reported better-than-expected second-quarter adjusted EPS results and issued its FY25 guidance above estimates.
G-III Apparel Group reported second-quarter adjusted earnings per share of 52 cents, beating the analyst consensus of 27 cents. Quarterly revenues of $644.75 million (down 2%) missed the street view of $649.44 million.
G-III Apparel Group shares surged 23.6% to $30.95 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares jumped 68.1% to $5.45 after the company entered agreements for a $160 million private placement financing priced at market, from a group of institutional and accredited investors including NVIDIA and Related Companies.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) gained 14.9% to $21.15.</li>
<li>Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) climbed 13.5% to $8.81.</li>
<li>Uniti Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) rose 13.3% to $5.32.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) climbed 13% to $5.56 after the company reported better-than-expected second-quarter adjusted EPS results and issued FY25 revenue guidance above estimates. Also, Needham upgraded the stock from Hold to Buy and announced an $8 price target.</li>
<li>Perpetua Resources Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) rose 11.8% to $9.05 after the company announced the U.S. forest service has completed the final environmental impact statement and issued a draft record of decision authorizing the Stibnite gold project.</li>
<li>Vestis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) gained 11.7% to $15.28 following a report suggesting Elis SA made an offer to buy the company.</li>
<li>WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) climbed 10.7% to $18.63.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) gained 10.4% to $4.6850 after the company reported second-quarter financial results and issued better-than-expected third-quarter outlook..</li>
<li>Shoe Carnival, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) rose 10% to $41.32 after the company reported better-than-expected second-quarter revenue results. Also, the company raised its FY24 guidance.</li>
<li>Primo Water Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRMW#NASDAQ">PRMW</a>) gained 9.4% to $23.92.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) gained 8.5% to $43.79. Craig-Hallum analyst Alexander Nowak upgraded QuidelOrtho from Hold to Buy and raised the price target from $40 to $57.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 8.3% to $1.3095.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) gained 7.9% to $27.36.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) gained 7.8% to $26.83. Zeta Global priced $204.9 million public offering of 13.2 million class A common shares at $23.50 per share.</li>
<li>Sotera Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) gained 7.7% to $16.59. The company announced a secondary offering of 25 million shares.</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) rose 6.2% to $67.52. Dollar Tree, on Wednesday, reported worse-than-expected second-quarter 2024 earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40728954/how-to-earn-500-a-month-from-smith-wesson-brands-stock-ahead-of-q1-earnings-report">How To Earn $500 A Month From Smith &amp; Wesson Brands Stock Ahead Of Q1 Earnings Report</a></li>
</ul>

Intraday Update

APLD

DLTR

GIII

Larimar Therapeutics, Inc. - Common Stock

LRMR

PPTA

PRMW

PSNY

QDEL

SATS

SCVL

UNIT

VSTS

YEXT

ZETA

G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday

WIIM

Myriad Genetics shares are trading lower after the company announced that it discontinued the second part of its study due to the disparities between the GeneSight Group and control group.

Myriad Genetics Said Due To Significant Disparities Between GeneSight Group And Control Group, Myriad Concluded That The Control Group Was Not Viable, Leading To The Discontinuation Of The Second Part Of The Study

Myriad Genetics Non-GAAP EPS of $0.06 beats by $0.04, revenue of $213.3M beats by $2.51M

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price tar...

Cautious Hold Recommendation for Myriad Genetics Amid GeneSight Coverage Challenges and Mixed Revenue Signals

Myriad Genetics ( ($MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors. Myriad...

Myriad Genetics Reports Solid Q3 2024 Growth Amid Challenges

Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript

Analyst Puneet Souda of Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), reducing the price target to $30.00. ...

Myriad Genetics: Overcoming Setbacks with Strategic Resilience and Growth Prospects

Piper Sandler lowered the firm's price target on Myriad Genetics (MYGN) to $24 from $30 following quarterly results. The firm keeps a Neutral ratin...

Myriad Genetics price target lowered to $24 from $30 at Piper Sandler

Scotiabank lowered the firm's price target on Myriad Genetics (MYGN) to $24 from $34 and keeps an Outperform rating on the shares. The firm lowered...

Myriad Genetics price target lowered to $24 from $34 at Scotiabank

Life sciences stocks viewed positively at TD Cowen despite post-election weakness

Morgan Stanley lowered the firm's price target on Myriad Genetics (MYGN) to $21 from $32 and keeps an Equal Weight rating on the shares. Q3 results...

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

Myriad Genetics (MYGN) announced that the Prequel Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its AMPLIFY technology...

Myriad announces Prequel Prenatal Screening can be performed at 8 weeks

ADPT

AVTR

BRKR

EXAS

MDXH

NTRA

PACB

RVTY

Press Releases

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

Legal

Health Care

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Comments

Myriad Genetics

空売り

Myriad Genetics (NASDAQ:MYGN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル